Finance

Lists
Why is OCUL down 3.53%?
Dive Deeper
OCUL:NASDAQ
Ocular Therapeutix Inc
US$6.42
-3.53%
(-0.23) 1D
ኖቬም 12, 12:47:21 ከሰዓት ጂ ኤም ቲ-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for OCUL...
Open
US$6.51
High
US$6.66
Low
US$6.29
Mkt. cap
1.41 ቢ
Avg. vol.
3.10 ሚ
Volume
894.33 ሺ
52-wk high
US$16.44
52-wk low
US$6.00
EPS
-US$1.46
Beta
1.22
Shares outstanding
220.02 ሚ
No. of employees
325
Open
US$6.51
High
US$6.66
Low
US$6.29
Mkt. cap
1.41 ቢ
Avg. vol.
3.10 ሚ
Volume
894.33 ሺ
52-wk high
US$16.44
52-wk low
US$6.00
EPS
-US$1.46
Beta
1.22
Shares outstanding
220.02 ሚ
No. of employees
325
News stories
From web sources and news partners
About Ocular Therapeutix Inc
CEOPravin Dugel
Employees325
Founded2006
HeadquartersBedford, ማሣቹሰትስ, ዩናይትድ ስቴትስ
SectorHealth Care
IndustryPharmaceutical industry
Websiteocutx.com
Analyst ratings
Based on 8 analysts giving stock ratings to OCUL in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for OCUL in the last 3 months.
Highest
Current US$6.42
US$31.00 (+382.49%)
Average
US$25.14 (+291.28%)
Lowest
US$14.00 (+117.90%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yi Chen
H.C. Wainwright
Buy
Reiterated
US$28.00
+335.8%
11/10/2026
Serge Belanger
Needham
Buy
Maintained
US$18.00
+180.2%
11/10/2026
Lisa Walter
RBC Capital
Buy
Reiterated
US$30.00
+366.9%
11/09/2026
Tazeen Ahmad
Bank of America Securities
Buy
Reiterated
US$27.00
+320.2%
11/09/2026
Biren Amin
Piper Sandler
Buy
Maintained
US$31.00
+382.5%
10/12/2026
Unknown Analyst
UBS
Buy
Initiated
US$14.00
+117.9%
10/11/2026
Alice Nettleton
UBS
Buy
Initiated
US$14.00
+117.9%
10/11/2026
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
09/25/2026
William Maughan
Clear Street
Buy
Reiterated
US$28.00
+335.8%
08/18/2026
Tara Bancroft
TD Cowen
Buy
Maintained
US$20.00
+211.3%
08/03/2026
Daniil Gataulin
Chardan Capital
Buy
Maintained
US$23.00
+258%
06/25/2026
Colleen M. Kusy
Robert W. Baird
Buy
Maintained
US$30.00
+366.9%
06/18/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
-
-
02/17/2026
Clara Dong
Jefferies
Buy
Maintained
US$28.00
+335.8%
02/17/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ዲሴም 2025
ማርች 2026
ጁን 2026
ሴፕቴ 2026
Revenue
13.25 ሚ
10.78 ሚ
13.48 ሚ
12.87 ሚ
Cost of goods sold
52.39 ሚ
67.54 ሚ
56.15 ሚ
76.24 ሚ
Cost of revenue
52.39 ሚ
67.54 ሚ
56.15 ሚ
76.24 ሚ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
30.62 ሚ
36.58 ሚ
39.44 ሚ
34.49 ሚ
Operating expense
30.62 ሚ
36.58 ሚ
39.44 ሚ
34.49 ሚ
Total operating expenses
83.01 ሚ
104.12 ሚ
95.58 ሚ
110.73 ሚ
Operating income
-69.76 ሚ
-93.34 ሚ
-82.11 ሚ
-97.86 ሚ
Other non operating income
624.00 ሺ
1.46 ሚ
689.00 ሺ
912.00 ሺ
EBT including unusual items
-64.65 ሚ
-88.61 ሚ
-78.76 ሚ
-94.78 ሚ
EBT excluding unusual items
-64.62 ሚ
-88.61 ሚ
-78.76 ሚ
-94.78 ሚ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-64.65 ሚ
-88.61 ሚ
-78.76 ሚ
-94.78 ሚ
Net profit margin
-487.95%
-821.62%
-584.51%
-736.23%
Earnings per share
-0.29
-0.40
-0.35
-0.42
Interest and investment income
7.34 ሚ
6.05 ሚ
5.45 ሚ
4.98 ሚ
Interest expense
-2.83 ሚ
-2.78 ሚ
-2.79 ሚ
-2.81 ሚ
Net interest expenses
4.51 ሚ
3.27 ሚ
2.66 ሚ
2.16 ሚ
Depreciation and amortization charges
-
-
-
-
EBITDA
-68.51 ሚ
-92.06 ሚ
-80.26 ሚ
-95.43 ሚ
Gain or loss from assets sale
-
4.87 ሚ
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google መተግበሪያዎች